首页> 外文期刊>Human gene therapy. Clinical development >Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy
【24h】

Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy

机译:使用造血基因疗法在线粒体神经元脑膜脑瘤病症中杂草基因疗法的长期恢复胸苷磷酸化酶函数和核苷稳态

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a metabolic disorder caused by mutations in TYMP, encoding thymidine phosphorylase (TP). In MNGIE patients, TP dysfunction produces systemic thymidine and deoxyuridine accumulation, which ultimately impairs mitochondrial DNA replication and results in mitochondrial dysfunction. To date, only allogeneic hematopoietic stem cell transplantation has demonstrated long-term clinical efficacy, but high morbidity and mortality associated with this procedure necessitate the search for safer alternatives. In a previous study, we demonstrated that hematopoietic stem cell gene therapy using a lentiviral vector containing the coding sequence of TYMP restored the biochemical homeostasis in an animal model of MNGIE. In the present follow-up study, we show that ectopic expression of TP in the hematopoietic system restores normal nucleoside levels in plasma, as well as in tissues affected in MNGIE such as small intestine, skeletal muscle, brain, and liver. Mitochondrial dNTP pool imbalances observed in liver of the animal model were also corrected by the treatment. The biochemical effects were maintained at least 20 months even with low levels of chimerism. No alterations in the blood cell counts or other toxic effects were observed in association with the lentiviral transduction or TP overexpression. These results further support the notion that gene therapy is a feasible treatment option for MNGIE.
机译:线粒体神经痛苦脑脑病(MIGIE)是由TMP中的突变引起的代谢障碍,编码胸苷磷酸化酶(TP)。在Mngie患者中,TP功能障碍产生全身胸苷和脱氧尿苷累积,这最终损害了线粒体DNA复制并导致线粒体功能障碍。迄今为止,只有同种异体造血干细胞移植均表现出长期的临床疗效,但与此程序相关的高发病率和死亡率需要搜索更安全的替代品。在先前的研究中,我们证明了使用含有TYMP编码序列的慢病毒载体的造血干细胞基因治疗在MNGIE的动物模型中恢复生化稳态。在目前的后续研究中,我们表明TP在造血系统中的异位表达恢复血浆中正常的核苷水平,以及在MGie中受影响的组织中,如小肠,骨骼肌,脑和肝脏。在动物模型的肝脏中观察到的线粒体DNTP池不平衡也通过治疗纠正。即使具有低水平的斜切性,生物化学效果至少保持20个月。与慢病毒转导或TP过表达相关联,观察到血细胞计数或其他毒性作用的改变。这些结果进一步支持基因治疗是MIGIE的可行治疗选择的观点。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号